Stay updated on Nivolumab for Peripheral T-cell Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Nivolumab for Peripheral T-cell Lymphoma Clinical Trial page.

Latest updates to the Nivolumab for Peripheral T-cell Lymphoma Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedAdded a Locations section with Minnesota as a site. Removed HHS Vulnerability Disclosure and Minnesota Locations entries; updated revision to v3.3.3.SummaryDifference0.2%

- Check26 days agoNo Change Detected
- Check40 days agoChange DetectedRevision: v3.3.2 is displayed, replacing Revision: v3.3.1. No substantive study details or page content were changed.SummaryDifference0.0%

- Check48 days agoChange DetectedPublications section updated to note that entries are automatically filled from PubMed and may not be about the study, and the revision is updated to v3.3.1.SummaryDifference0.1%

- Check55 days agoChange DetectedNotice about government funding lapse and potential delays was removed from the page.SummaryDifference0.3%

- Check69 days agoChange DetectedThe screenshots show only minor formatting and layout adjustments with no changes to study content or eligibility criteria. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check98 days agoChange DetectedUpdated page version to v3.2.0 and added a government-operating-status notice; removed several specific disease entries from the content.SummaryDifference3%

Stay in the know with updates to Nivolumab for Peripheral T-cell Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab for Peripheral T-cell Lymphoma Clinical Trial page.